Ultra-short-course and intermittent TB47-containing oral regimens produce stable cure against Buruli ulcer in a murine model and prevent the emergence of resistance for Mycobacterium ulcerans

• Main Authors: Yamin Gao (Author), H.M. Adnan Hameed (Author), Yang Liu (Author), Lingmin Guo (Author), Cuiting Fang (Author), Xirong Tian (Author), Zhiyong Liu (Author), Shuai Wang (Author), Zhili Lu (Author), Md Mahmudul Islam (Author), Tianyu Zhang (Author)
• 格式: 圖書
• 出版: Elsevier, 2021-03-01T00:00:00Z.
• 主題: article
• 在線閱讀: Connect to this object online.

Buruli ulcer (BU), caused by Mycobacterium ulcerans, is currently treated with rifampin-streptomycin or rifampin-clarithromycin daily for 8 weeks recommended by World Health Organization (WHO). These options are lengthy with severe side effects. A new anti-tuberculosis drug, TB47, targeting QcrB in...